Tourbillon’s Big Short Pays Off in Q3

October 17, 2016   Stephen Taub

Read more:

Jason Karp’s firm posted a strong third quarter in part due to the collapsing price of a struggling biotech company.

Shares of biotechnology firm MannKind Corp., which specializes in therapeutic products for diabetes and has been in free fall lately, plummeted another 8 percent or so on Friday, to close at a new low of about $0.50 per share. This …


Subscribers have unlimited access to all online content inc rankings. Start your subscription today - click on the button below.

Subscribe now

Free trial

Taking a free trial will give you access to online content one week (excludes research & rankings). Start your trial today.

Free Trial

Latest Poll

How will hedge funds finish 2017?

 - 72%
 - 11%
 - 17%

View previous results